Biomea Fusion's oral GLP-1 agonist BMF-650 showed 1.5–3.2% weight loss in Phase I outpatient cohorts over four weeks. Read ...
Equillium receives Australian clearance to start the first-in-human EQ504 trial for ulcerative colitis. Read how dosing ...
Alaunos Therapeutics completes its acquisition of Velaris Therapeutics, adding an ActRII-Fc PAH pipeline backed by a $350M ...
Roche secures exclusive worldwide license to Rona Therapeutics' ALK7 RNAi obesity therapy in a deal worth up to $1.16B. Read ...
MicuRx will out-license preclinical ADC MRX-23 to ClearideBio, plus a STOPIN platform deal, worth up to USD 974 million. Read the full deal breakdown now.
BioNTech's BNT113 misses Phase III PFS endpoint in HPV16-positive head and neck cancer. Read the full trial update and what ...
Visara licenses VIS-102 nerve growth factor therapy for neurotrophic keratitis in a USD 111m deal. Read the full story on ...
Sloan-Kettering Institute gets a $1.5M FDA grant to map therapeutic targets in ultra-rare sarcomas. Learn how it may advance ...
Undecimal Bio raises $18M seed funding to extend siRNA delivery beyond the liver. Discover how this biotech's DELiveri ...
AMPfield's once-daily prifemilast beat apremilast on both co-primary endpoints in a Phase III psoriasis head-to-head trial.
Remigromig met the non-inferiority endpoint vs ranibizumab in the BRUNELLO DME trial, but PDR adverse events were higher.
Bristol Myers Squibb's admilparant met the Phase III ALOFT-IPF primary endpoint, showing significant FVC gains in pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results